share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(14.8%),Stockton Limited(14.8%), etc.

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nirland Limited(14.8%),Stockton Limited(14.8%), etc.

SC 13G/A：超過5%持股股東披露文件(修正)-Nirland Limited(14.8%),Stockton Limited(14.8%)等
美股SEC公告 ·  08/14 04:33
牛牛AI助理已提取核心訊息
Conduit Pharmaceuticals Inc. has been the subject of an amended Schedule 13G filing with the United States Securities and Exchange Commission (SEC), dated August 13, 2024. The amendment, which supplements the original filing from October 2, 2023, discloses that Nirland Limited, along with related entities Stockton Limited, The Rowland Master Trust, and Dovet Limited, collectively hold a 14.8% ownership stake in Conduit Pharmaceuticals. This stake amounts to 14,500,000 shares of common stock. The shares include 12,500,000 directly issued to Nirland Limited and an additional 2,000,000 shares potentially issuable upon the exercise of a common stock warrant. The entities are all registered in Guernsey and are interconnected through ownership and trust relationships, with Dovet Limited acting as the sole trustee of The Rowland Master Trust, which wholly owns Stockton Limited, which in turn owns Nirland Limited. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.
Conduit Pharmaceuticals Inc. has been the subject of an amended Schedule 13G filing with the United States Securities and Exchange Commission (SEC), dated August 13, 2024. The amendment, which supplements the original filing from October 2, 2023, discloses that Nirland Limited, along with related entities Stockton Limited, The Rowland Master Trust, and Dovet Limited, collectively hold a 14.8% ownership stake in Conduit Pharmaceuticals. This stake amounts to 14,500,000 shares of common stock. The shares include 12,500,000 directly issued to Nirland Limited and an additional 2,000,000 shares potentially issuable upon the exercise of a common stock warrant. The entities are all registered in Guernsey and are interconnected through ownership and trust relationships, with Dovet Limited acting as the sole trustee of The Rowland Master Trust, which wholly owns Stockton Limited, which in turn owns Nirland Limited. The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.
Conduit Pharmaceuticals Inc.已成爲2024年8月13日美國證券交易委員會（SEC）修訂後的13G表格申報的對象。該修訂內容補充了自2023年10月2日起的原有申報書，在其中披露了Nirland有限公司，與相關實體Stockton有限公司，The Rowland Master Trust和Dovet有限公司共同持有Conduit Pharmaceuticals 14.8％的所有權。這些股份相當於1450萬股普通股。其中1,250萬股直接發行給Nirland有限公司，另外2,000,000股則是在按照普通股認股權行使可能性下發放的。這些實體均在根西島註冊，並通過所有權和...展開全部
Conduit Pharmaceuticals Inc.已成爲2024年8月13日美國證券交易委員會（SEC）修訂後的13G表格申報的對象。該修訂內容補充了自2023年10月2日起的原有申報書，在其中披露了Nirland有限公司，與相關實體Stockton有限公司，The Rowland Master Trust和Dovet有限公司共同持有Conduit Pharmaceuticals 14.8％的所有權。這些股份相當於1450萬股普通股。其中1,250萬股直接發行給Nirland有限公司，另外2,000,000股則是在按照普通股認股權行使可能性下發放的。這些實體均在根西島註冊，並通過所有權和信託關係相互關聯，Dovet有限公司擔任The Rowland Master Trust的唯一受託人，後者完全擁有Stockton有限公司，後者又擁有Nirland有限公司。申報書表明這些股份並非爲了改變或影響Conduit Pharmaceuticals的控制而收購的。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。